Pulmonary Hypertension articles & resources on Made-in-China.com

More Standardised Methods Are Needed for The Extemporaneous Preparation

Jan 10, 2014

More standardised methods are needed for the extemporaneous preparation of paediatric medicines, indicates a doctoral dissertation examined at the University of Eastern Finland. Hospital pharmacies modify adult medicines for children when ...

Tags: standardised methods, paediatric medicines, children health, medicines

Ikaria Would Sell The Commercial Business to Madison Dearborn Partners

Dec 30, 2013

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients, announced today that its investor group and employee shareholders ...

Tags: Ikaria, sell the Commercial Business, Madison Dearborn Partners

Bayer HealthCare Pharmaceuticals Has Obtained FDA Approval for Its Adempas Tablets

Oct 11, 2013

Bayer HealthCare Pharmaceuticals, a subsidiary of Bayer, has obtained the US Food and Drug Administration (FDA) approval for its Adempas (riociguat) tablets. Adempas tablets are developed for the treatment of adults with ...

Tags: Bayer Healthcare, Riociguat Tablets

Bayer HealthCare Pharmaceuticals Has Obtained Two Separate Orphan Drug Designations

Sep 27, 2013

Bayer HealthCare Pharmaceuticals, a subsidiary of Bayer, has obtained two separate orphan drug designations from the US Food and Drug Administration's (FDA) Office of Orphan Products Development for its investigational, oral medication ...

Tags: Drug Designations, Medicine

FDA Cardiovascular and Advisory Committee Has Recommended Approval of Oral sGC Stimulator

Aug 9, 2013

The US Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee has recommended approval of Bayer’s oral soluble guanylate cyclase (sGC) stimulator, riociguat, in two forms of pulmonary ...

Tags: FDA Advisory Committee

Germany-Based Activaero Has Extended Its Collaboration Agreement with Transmit

Apr 26, 2013

Germany-based Activaero has extended its collaboration agreement with TransMIT, Gesellschaft für Technologietransfer, the technology transfer agency of Justus-Liebig-University Giessen, to develop the treatment of pulmonary ...

Tags: Pulmonary Hypertension, Health

Ventripoint's Vms-2de Heart Analysis System Has Obtained CE Mark

Apr 23, 2013

Ventripoint Diagnostics has obtained CE mark certification from European notified body Intertek Semko for its NRV application for the VMS-2DE heart analysis system. The NRV database can be used in conjunction with right heart analysis ...

Tags: Ventripoint, CE Mark, NRV Application

GeNO Obtains a Clearance for Its Inhaled NO Delivery System, GeNOsyl MV-1000, From FDA

Dec 14, 2012

GeNO has obtained a clearance for its inhaled nitric oxide (NO) delivery system, GeNOsyl MV-1000, from the US Food and Drug Administration (FDA). GeNOsyl MV-1000 system, which incorporates a primary delivery system, a backup system, ...

Tags: FDA, inhaled nitric oxide delivery system, clinical product, GeNO

GeNO Receivs Four US Patents for NO Generation Chemistry and Delivery Technology

Dec 14, 2012

GeNO has received four additional US patents for its proprietary nitric oxide (NO) generation chemistry and delivery technology. The patent No. 8,211,368 describes the conversion of nitrogen dioxide (NO2) to NO where NO2 is stored as ...

Tags: US patent, clinical technology, clinical research, GeNO

GeNO Received Four Additional US Patents

Dec 5, 2012

Inhaled nitric oxide drug products developer GeNO has received four additional US patents on its proprietary inhaled nitric oxide (NO) generation chemistry and delivery technology, bringing the total number of US patents to sixteen. The ...

Tags: inhaled nitric oxide drug, NO, NO2, GeNO

FDA Has Accepted Geno's Filing of NDA for MVG

Nov 27, 2012

The US Food and Drug Administration (FDA) has accepted GeNO's filing of new drug application (NDA) for GeNOsyl MVG-2000 nitric oxide delivery system. GeNOsyl nitric oxide is a vasodilator which is indicated for the treatment of term and ...

Tags: GeNOsyl nitric oxide, FDA

Orphan Drug Designation Was Granted Based on a Plausible Hypothesis

Aug 15, 2012

The US Food and Drug Administration (FDA) has granted orphan drug designation to GeNO for use of inhaled nitric oxide (NO) in treatment of persistant pulmonary hypertension of the newborn (PPHN). The orphan drug designation was granted ...

Tags: orphan drug designation, FDA, persistant pulmonary hypertension

Pulmonary Hypertension

Related Products